DECREASED RISK FOUND AFTER MRNA VACCINE Having a COVID-19 infection is associated with an increased risk of developing the rare disorder called Guillain-Barré syndrome within the next six weeks, according to a study published in the October 18, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study also
Tens of thousands of people in England may have lasting symptoms from COVID‐19 more than a year after infection, new analysis reveals. The findings come from a representative sample of more than a quarter of a million people in England surveyed as part of the REACT study, who self-reported their symptoms and the impact of COVID-19
In a study published in The New England Journal of Medicine, clinicians and researchers from the CHU of Liège and the University of Liège show that the administration of plasma taken from convalescent donors after infection with Sars-CoV-2 to patients suffering from acute respiratory distress syndrome requiring artificial mechanical ventilation significantly reduced mortality (10%). he randomised
Researchers have identified 38 businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies for preventing and treating COVID-19 even though these “interventions” have not been approved or authorized by national regulatory bodies and are not supported by convincing safety and efficacy data. The analysis, appearing in the journal Stem Cell Reports, also found
Brazilian researchers and collaborators in Germany and the US compiled data from 195 clinical trials conducted in 30 countries between January 2020 and December 2021. The findings are promising, although the authors stress the need for enhanced controls in the making of the products used in cell therapy. Their findings are reported in an article
In an updated rapid, living practice points, the American College of Physicians (ACP) summarizes the latest evidence on the use of pharmacologic and biologic treatments of COVID-19 in the outpatient setting, specifically addressing the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant. Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points from the American
More and more frequent vaccine doses than in other countries reduce mortality in covid-19 in nursing homes. This is shown by a Swedish study, led by Anders Johansson and Mattias Forsell, Umeå University, which was published in the highly ranked journal Lancet Infectious Diseases. In the fight against covid-19, researchers have carefully studied the effectiveness
Type 1 diabetes is an autoimmune disease leading to an impaired glucose metabolism and requires life-long administration of insulin. While the cause of the autoimmunity reaction is still unclear, viral infections in young children are proposed to be critical environmental factors leading to type 1 diabetes. An international team of researchers from the Global Platform
There has been so much new on this since my quick update 2 weeks ago, I need to dedicate this newsletter to reviewing what’s up. First Human Data for the New Booster Let me start with the good news from the first human data for the new monovalent XBB.1.5 vaccine that is getting set for distribution
NIH-funded research effort identifies most common symptoms, potential subgroups, and initial symptom-based scoring system – with aim of improving future diagnostics and treatment. Initial findings from a study of nearly 10,000 Americans, many of whom had COVID-19, have uncovered new details about long COVID, the post-infection set of conditions that can affect nearly every tissue
